Cargando…

DS-7080a, a Selective Anti-ROBO4 Antibody, Shows Anti-Angiogenic Efficacy with Distinctly Different Profiles from Anti-VEGF Agents

PURPOSE: Neovascular age-related macular degeneration (nAMD) results from choroidal neovascularization (CNV) and causes severe vision loss. Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly improved therapeutic outcomes; however, a substantial number of patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isumi, Yoshitaka, Hayashi, Shinko, Inoue, Tatsuya, Yoshigae, Yasushi, Sato, Toshiyuki, Hasegawa, Jun, Agatsuma, Toshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442859/ https://www.ncbi.nlm.nih.gov/pubmed/32879763 http://dx.doi.org/10.1167/tvst.9.9.7

Ejemplares similares

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
por: Keizer, Ron J., et al.
Publicado: (2010)

Novel anti-EPHA2 antibody, DS-8895a for cancer treatment
por: Hasegawa, Jun, et al.
Publicado: (2016)

Anti-angiogenic alternatives to VEGF blockade
por: Khan, Kabir A., et al.
Publicado: (2015)

Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
por: Itatani, Yoshiro, et al.
Publicado: (2018)

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti–CTLA-4 antibody in a mouse model
por: Iwata, Tomomi Nakayama, et al.
Publicado: (2019)

Anti‐ORAI1 antibody DS‐2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T‐cell and mast cell activation
por: Aki, Anri, et al.
Publicado: (2020)

Anti-VEGF-A Affects the Angiogenic Properties of Tumor-Derived Microparticles
por: Munster, Michal, et al.
Publicado: (2014)

Anti-Angiogenic Effect of Asperchalasine A Via Attenuation of VEGF Signaling
por: Park, Jun Yeon, et al.
Publicado: (2019)

Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling
por: Stratman, Amber N., et al.
Publicado: (2020)

Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy
por: van Beijnum, Judy R., et al.
Publicado: (2022)

The endogenous anti-angiogenic VEGF isoform, VEGF(165)b inhibits human tumour growth in mice
por: Rennel, E S, et al.
Publicado: (2008)

Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
por: Harris, Sheila, et al.
Publicado: (2012)

The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy
por: Carter, James G., et al.
Publicado: (2014)

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
por: Guyot, Mélanie, et al.
Publicado: (2016)

Direct and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
por: Bourhis, Morgane, et al.
Publicado: (2021)

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
por: Scheuer, Werner, et al.
Publicado: (2016)

Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
por: Ogitani, Yusuke, et al.
Publicado: (2016)

An anti-angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease
por: Kikuchi, Ryosuke, et al.
Publicado: (2014)

Anti-Angiogenic and Anti-Metastatic Activity of Synthetic Phosphoethanolamine
por: Ferreira, Adilson Kleber, et al.
Publicado: (2013)

The Anti-Angiogenic and Anti-Proliferative Activity of Methyl Hydroxychalcone
por: Sahib, Hayder B
Publicado: (2022)

Mithramycin Exerts an Anti-Myeloma Effect and Displays Anti-Angiogenic Effects through Up-Regulation of Anti-Angiogenic Factors
por: Otjacques, Eléonore, et al.
Publicado: (2013)

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
por: Stahl, Andreas, et al.
Publicado: (2012)

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities
por: Wang, Lei, et al.
Publicado: (2021)

Sales for anti-angiogenic drugs
por: Ribatti, Domenico
Publicado: (2017)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

Anti-Oxidant, Anti-Inflammatory and Anti-Angiogenic Properties of Resveratrol in Ocular Diseases
por: Lançon, Allan, et al.
Publicado: (2016)

Anti-VEGF and Beyond
por: Bertelmann, T., et al.
Publicado: (2017)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Anti-tumor and Anti-angiogenic Ergosterols from Ganoderma lucidum
por: Chen, Shaodan, et al.
Publicado: (2017)

The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
por: Barillari, Giovanni
Publicado: (2020)

The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy
por: Pożarowska, Dorota, et al.
Publicado: (2016)

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants
por: Shumaker, Robert, et al.
Publicado: (2015)

Binding and Efficacy of Anti-Robo4 CAR-T Cells against Solid Tumors
por: Hirobe, Sachiko, et al.
Publicado: (2022)

A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition
por: Labanca, Valentina, et al.
Publicado: (2016)

Regulation of Vascular Endothelial Growth Factor (VEGF) Splicing from Pro-angiogenic to Anti-angiogenic Isoforms: A NOVEL THERAPEUTIC STRATEGY FOR ANGIOGENESIS
por: Nowak, Dawid G., et al.
Publicado: (2010)

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo
por: Foy, Kevin C., et al.
Publicado: (2012)

The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Reactive resistance to anti-angiogenic drugs
por: Bousquet, Guilhem, et al.
Publicado: (2015)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kjq6ars66nl5i7po4n2slbr9ht